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A novel coronavirus (CoV) has been identified as the etiological agent of severe acute respiratory syndrome
(SARS). The SARS-CoV genome encodes the characteristic essential CoV replication and structural proteins.
Additionally, the genome contains six group-specific open reading frames (ORFs) larger than 50 amino acids,
with no known homologues. As with the group-specific genes of the other CoVs, little is known about the
SARS-CoV group-specific genes. SARS-CoV ORF7a encodes a putative unique 122-amino-acid protein, desig-
nated U122 in this study. The deduced sequence contains a probable cleaved signal sequence and a C-terminal
transmembrane helix, indicating that U122 is likely to be a type I membrane protein. The C-terminal tail also
contains a typical endoplasmic reticulum (ER) retrieval motif, KRKTE. U122 was expressed in SARS-CoV-
infected Vero E6 cells, as it could be detected by Western blot and immunofluorescence analyses. U122 is
localized to the perinuclear region of both SARS-CoV-infected and transfected cells and colocalized with ER
and intermediate compartment markers. Mutational analyses showed that both the signal peptide sequence
and ER retrieval motif were functional.
An outbreak of atypical pneumonia, severe acute respiratory
syndrome (SARS) is thought to have originated from Guang-
dong Province, Republic of China in late 2002. The mortality
rate of individuals suffering from SARS can be as high as 15%
(1), depending on the age group analyzed. A novel coronavirus
(CoV) has recently been shown to fulfill all of Koch’s postu-
lates as the primary aetiological agent of SARS, including
outcomes of monkey trials (5, 13). SARS-CoV contains a ge-
nome of29.7 kbs that encodes the usual CoV replication and
structural proteins.
CoVs are positive-sense RNA, enveloped viruses that con-
tain genomes of about 30 kb (9). Traditionally, the CoVs are
divided into three groups that include the mammalian viruses
in groups 1 and 2 and avian viruses in group 3. The viruses are
further classified into species within each group, based on host
range, antigenic relationships, and genomic organization (20).
All known CoVs have a common set of essential genes
encoding nonstructural proteins involved in replication (repli-
case gene 1ab) and structural proteins (nucleocapsid, mem-
brane [M], envelope [E], and spike [S]) that are assembled into
viral particles (10). Interspersed among these genes are group-
specific open reading frames (ORFs), the majority of whose
functions have yet to be established. Research on the possible
functions of these genes has been limited, but they appear to
be nonessential, accessory genes in cell culture (3). Inactivation
of group-specific mouse hepatitis virus ORF4 did not affect
growth kinetics or cytopathogenicity, indicating that it is not
required for growth in cell culture (18). Interestingly, however,
deletion of the nonessential genes from the mouse hepatitis
virus genome resulted in attenuated viruses when inoculated
into their natural hosts (3), indicating a possible in vivo func-
tion. On the other hand, Shen et al. (22) showed that contin-
uous passage of infectious bronchitis virus (IBV) in cells re-
sulted in mutations in the 3b gene of IBV. These mutations
resulted in a growth advantage in cells and chicken embryos, as
well as in an increase in virulence in the embryos.
Most CoVs are fairly host specific, sometimes causing severe
upper respiratory or intestinal disease in the host species (9,
14). The human CoVs found in both groups 1 and 2 cause
about 30% of colds in humans but rarely cause lower respira-
tory tract disease (9). Sequence analyses indicate that SARS-
CoV is distinct from all known CoVs. Initial reports concluded
that SARS-CoV did not belong to any of the three existing
CoV groups (16, 20). More recent phylogenetic analysis, how-
ever, has identified SARS-CoV as distantly related to members
of the group 2 CoVs (23).
This study reports the characterization of the SARS-CoV
group-specific gene product encoded by ORF7a (also known as
ORFX4 or ORF8) (Fig. 1) (16, 20, 23), which we refer to as
U122 (designating a unique protein of 122 amino acids [aa]).
To understand the role, if any, that U122 plays in the infectivity
of SARS-CoV, characterization of the gene and its product is
required. Sequence analysis predicted a 122-aa polypeptide,
with a putative signal peptide sequence, C terminus transmem-
brane domain, and short cytoplasmic tail containing the endo-
plasmic reticulum (ER) retrieval motif KRKTE (Fig. 2A).
Using Western blot and immunofluorescence, we show that
U122 was expressed in SARS-CoV-infected cells. The initial
characterization of the localization and processing of U122 is
presented in this paper. Additionally, mutational analysis was
used to characterize the putative signal peptide and ER re-
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trieval sequences. Further work to determine if U122 performs
an essential function in viral replication and pathogenesis will
be carried out.
MATERIALS AND METHODS
Viruses and cells lines. African green monkey kidney fibroblast (Vero E6)
cells (American Type Culture Collection, Manassas, Va.) were maintained in
complete Dulbecco’s modified Eagle medium (Gibco) containing 10% fetal calf
serum (HyClone Laboratories), 100 U of penicillin per ml, and 100 g of
streptomycin (Sigma) per ml. SARS-CoV strain SIN2774 (21) was used to infect
subconfluent Vero E6 plates at a multiplicity of infection of 0.1. Subsequently,
cells were harvested at the desired cytopathic effect (CPE), and total proteins
were extracted (24). IBV-infected Vero E6 cell lysates were used as negative
controls as indicated.
Raising antibodies to U122. The cDNA encoding aa 16 to 111 was cloned into
pGEX-4T-1 and transformed into Escherichia coli BL21(DE3) cells. These cells
were induced to express U122 (aa 16 to 111) with IPTG (isopropyl--D-thioga-
lactopyranoside) and allowed to grow for 4 h at 37°C. Glutathione transferase-
fusion proteins were purified, and the preparation was injected into mice for
raising polyclonal antibodies (25). After four injections, the mice were bled, and
the sera were tested for reactivity to U122. The antibodies showed specific
reactivity to U122 expressed in Vero E6 cells infected with the SARS virus or
transfected with a U122 expression construct (Fig. 2B and C).
Construction of plasmids and mutations. cDNAs were cloned into pXJ40-
3HA (GLAXO Group, Institute of Molecular and Cell Biology, Singapore,
Republic of Singapore) for the expression of untagged proteins in mammalian
cells; all constructs were untagged. All forward primers used were designed to
incorporate a Kozak sequence. To create untagged proteins, all reverse primers
(with the exception of mutL14-18R) contained the translation stop codon. The
full-length 366-bp SARS-CoV ORF7a was amplified by PCR by using forward
primer U122F1 (5-CGGGATCCACCATGGGAATGAAAAT-3) and reverse
primer U122R2 (5-CCGCTCGAGTCATTCTGTCTT-3) incorporating
BamHI and XhoI endonuclease restriction sites (underlined), respectively. The
amplicon was purified, digested, and cloned into the compatible restriction sites
of the expression vector to form pXJU122. To mutate the U122 signal peptide
cleavage site, the amino acids SCELY located at positions 14 to 18 were mutated
to leucines LLLLL by a two-step PCR-directed mutagenesis approach (27) using
plasmid pXJU122 as a template. Briefly, the overlapping primer set consisting of
forward primer mutL14-18F (5-GTATTTACATTGTTGCTGCTACTTCACT
ATCAGGAG-3) and reverse primer mutL14-18R (5-CCTGATAGTGAAGT
AGCAGCAACAATGTAAATACAATC-3) containing the incorporated muta-
tions (underlined), were used in combination with primers U122F1 and U122R2
to create amplicon U122-L. The amplicon was purified, digested, and cloned in
the vector to create pXJU122L. Plasmid pXJmatU122 consisting of residues 16
to 122 was constructed by using PCR with forward primer U122F2, 5-CGGG
ATCCATGGAGCTATATCACT-3, and reverse primer U122R2; the BamHI
restriction site is underlined and the incorporated ATG is indicated in bold. To
study the signal retrieval motif the lysine residues in the 3-terminal amino acids
KRKTE at positions 118 and 120 were mutated to glutamic acid residues. This
was done by using PCR with forward primer U122F1 and reverse primer
U122RKE (5-CCGCTCGAGTCATTCTGTCTCTCTCAAT-3; the XhoI re-
striction site is underlined). This construct (pXJU122KE) expresses the un-
tagged retrieval mutant. All sequences were confirmed by DNA sequencing.
In vitro transcription and translation. A total of 0.5 g of plasmid pXJU122
was transcribed and translated by using the TNT T7 coupled reticulocyte lysate
system (Promega) in a 10-l reaction mixture for 1.5 h at 30°C. [35S]cysteine
(1,000Ci/mmol; NEN) was used to label U122, and samples were immunopre-
cipitated by using U122-specific antibodies with protein A-Sepharose. Proteins
were resolved on sodium dodecyl sulfate (SDS)–15% polyacrylamide gel elec-
trophoresis (PAGE) gels and visualized by radioautography with Amplify re-
agent (Amersham).
Transfection, pulse-chase radiolabeling, and immunoprecipitation. The trans-
fection of recombinant plasmids was accomplished by using liposomes (Lipo-
fectamine 2000 reagent; Invitrogen). Generally, for a 6-cm plate, 0.5 g of
plasmid DNA was used for transfection according to the manufacturer’s protocol.
For pulse-chase experiments, 2.0 g of plasmid DNA was used for transfection
per 6-cm plate. At 6 h posttransfection, confluent Vero E6 cells were starved for
30 min in prewarmed depletion medium lacking methionine and cysteine. The
depletion medium was replaced with medium containing 100 Ci of [35S]methi-
onine-cysteine mix per ml (EXPRE35S35S protein labeling mix; NEN) for 10 or
30 min. [35S]cysteine (100 Ci; NEN) was used to supplement the [35S]methi-
onine-cysteine mix to enhance the labeling efficiency. Subsequently, the cells
were washed and chased with complete Dulbecco’s modified Eagle medium
containing a 5 mM concentration of unlabeled methionine and cysteine. Radio-
immunoprecipitation assay (RIPA; 1) buffer was used to extract proteins, and
immunoprecipitation was done with protein A-Sepharose-coupled antibodies as
described by Nguyen and Hogue (17). Proteins were resolved by SDS–15%
PAGE, and gels were fixed and treated with Amplify fluorographic reagent
(Amersham). Subsequently, gels were dried and visualized by radioautography.
The amount of labeled U122 was quantified by using a Bio-Rad model GS-700
imaging densitometer with Bio-Rad Multi-Analyst version 1.02/Mac software
(number of radioautographs quantified for each experiment, 2).
Immunofluorescence of SARS-CoV-infected and transfected cells. SARS-
CoV-infected Vero E6 cells were grown on coverslips until they showed a CPE
of 25% (24). The coverslips were fixed in acetone for 20 to 30 min on ice and then
air dried before being stored at 20°C. Before use, the coverslips were fixed
again in methanol at20°C and air dried. For transfected proteins, Vero E6 cells
were grown on coverslips and transfected as described above. An immunofluo-
rescence assay was performed at about 16 h posttransfection as described by Goh
et al. (7). Briefly, the medium was removed, and the coverslips were fixed in
methanol for 5 min at 20°C, after which the coverslips were lifted out and
completely air dried. To decrease background staining, mouse anti-U122 sera
were adsorbed against fixed Vero E6 cells. Uninfected cells showed no back-
ground staining with absorbed mouse anti-U122 (Fig. 2C). Mouse anti-U122 was
used at a dilution of 1:200, and all other antibodies were used at dilutions of
1:100. Fixed cells were incubated with the appropriate primary antibody combi-
nation of mouse anti-U122 and rabbit anti-GS28 (Golgi marker; BD, Singapore,
Republic of Singapore) or rabbit anti-Sec31 (intermediate compartment marker
Sec31; HWJ Group, Institute of Molecular and Cell Biology, Singapore, Repub-
lic of Singapore). Following washing, cells were incubated with the secondary
antibody combination of fluorescein isothicyanate (FITC)-conjugated goat anti-
mouse and rhodamine (Rh)-conjugated antirabbit antibodies (Santa Cruz Bio-
chemicals). When cells were double-labeled with mouse anti-U122 and rat anti-
GRP94, fixed cells were sequentially incubated with rat anti-GRP94 (ER marker;
ITS Science and Medical, Singapore, Republic of Singapore) and FITC-conju-
gated anti-rat secondary antibody, followed by incubation with mouse anti-U122
and subsequently in Rh-conjugated antimouse (Santa Cruz Biochemicals). This
was done to minimize the cross-reaction of secondary antibodies with both the
primary antibodies.
RESULTS AND DISCUSSION
U122 expressed in SARS-CoV-infected cells. Sequence anal-
ysis of the SARS-CoV protein translated from ORF7a is pre-
FIG. 1. Genome organization of SARS-CoV. ORFs encoding the nonstructural proteins (black boxes), as well as ORFs encoding the structural
polypeptides (gray boxes) are indicated Also, selected ORFs encoding for putative accessory genes (unshaded boxes) are shown. ORF7a (also
called ORFX4 and ORF8) encoding peptide U122 is represented by the striated box. The ORFs shown are labeled according to Snijder et al. (23).
S, spike; N, nucleocapsid.
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dicted to be a 122-aa polypeptide containing a signal peptide at
the N terminus, a transmembrane domain, and a retrieval
signal at the C terminus (16, 20) (Fig. 2A).
To determine if U122 was expressed in SARS-CoV-infected
Vero E6 cells, cells were infected with SARS-CoV (strain
SIN2774) as described in Materials and Methods. Total pro-
teins were harvested from Vero E6 cells showing 25 and 50 to
75% CPE and subjected to Western blotting. No signal was
detected in mock-infected cells or IBV-infected cells (Fig. 2B,
lanes 1 and 5), indicating the specificity of the mouse antibody
against U122. By using our mouse anti-U122 antiserum, the
protein was only detected in SARS-CoV-infected cells at a
CPE of 50 to 75% (Fig. 2B, lane 3) and in Vero E6 cells
transfected with a U122 DNA construct (Fig. 2B, lane 4). Two
FIG. 2. U122 is expressed in SARS CoV-infected Vero E6 cells. (A) Analysis of the U122 putative sequence predicts a signal peptide sequence
(underlined) at the N terminus, the cleavage site of which is indicated with an arrow. A putative membrane-spanning domain (boxed) and an ER
retrieval motif (bold italics) are found at the C terminus. (B) Blots of Vero E6 cells probed with mouse anti-U122 antiserum. Lane 1, 20 g of
protein from uninfected cells; lanes 2 and 3, 20-g samples of proteins from SARS-CoV-infected cells harvested at about 25% CPE and 50 to 75%
CPE, respectively; lane 4, 15 g of total protein from cells transfected with pXJU122 plasmid; lane 5, 20 g of total lysate from an IBV-infected
cell culture. (C) Uninfected and virus-infected cells at 25% CPE were fixed and stained with mouse anti-U122 antibody. WB, Western blot;
m	U122, mouse anti-U122 antibody.
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bands of about 15.5 and 15.0 kDa were detected in SARS-CoV
late-infected cells (lane 3, 75% CPE), but a larger band of
17.5 kDa and a band of15.0 kDa were detected in transient
transfected cells expressing untagged U122 (lane 4). In SARS-
CoV-infected cells, the immature U122 may have been pro-
cessed efficiently, so that the immature form was not observed
in infected cells. There appeared to be an additional band
slightly larger than the mature form, indicating an intermedi-
ate form only present in virus-infected cells. U122 was not
detected in the early phase of infection (lane 2, 25% CPE),
even when the total protein of the sample with a 25% CPE that
was used for Western blotting and immunodetection was dou-
ble that of the sample with a 75% CPE (data not shown).
Immunofluorescence was used to determine the cellular lo-
calization of U122 in SARS-CoV-infected cells. By using
mouse anti-U122 antibody, the protein was detected in SARS-
CoV-infected Vero E6 cells (Fig. 2C). U122 was detected in
the perinuclear region and associated with ER. This cellular
localization is similar to that observed in U122-expressing
Vero E6 cells (see Fig. 5). We do not understand why U122
was clearly detected by immunofluorescence in infected cells at
25% CPE but not in Western blots of total proteins from cells
at 25% CPE. The antibodies may have stronger affinity to
conformational epitopes present in cells than to linear epitopes
that are present in denatured proteins on Western blots.
SARS-CoV U122 protein in transfected cells. The SARS-
CoV genome contains five group-specific ORFs larger than 50
amino acids (16, 20). SARS-CoV proteins, excluding the rep-
lication gene products of ORF 1ab, are translated from a set of
5 nested subgenomic mRNAs (sgmRNAs). Each sgmRNA
contains a 5 end derived from the genomic 5 leader sequence,
subgenomic sequences, and a common 3 end (8, 20, 26).
Between five and eight SARS-CoV sgmRNAs are detected by
Northern hybridization analysis from infected cells, ranging
from 8.3 to 1.7 kb in size (20, 23). This includes a polycistronic
2.5-kb mRNA that contains a conserved transcription regula-
tion sequence immediately upstream of ORF7a. This indicates
that ORF7a is likely to be translated (20) to give U122.
To express untagged SARS-CoV U122 in vitro, full-length
ORF7a was cloned into mammalian expression vector pXJ40-
3HA to form pXJU122. Untagged U122 was translated in
vitro by using the TNT coupled reticulocyte lysate system (Pro-
mega) in the presence of [35S]cysteine. Following immunopre-
cipitation with antibodies specific for U122, a single 17.5-
kDa band was observed (Fig. 3A). To detect U122 expressed in
Vero E6 cells, total proteins on Western blots were probed
with mouse anti-U122. Two bands of about 17.5 and 15.0 kDa
were observed (Fig. 3B, lane 3). The smaller protein band
could be due to proteolytic cleavage of the signal peptide and
was not observed in the in vitro translated product, even with
the addition of canine microsomal membranes (data not
shown), indicating the possible need for additional host cofac-
tor(s) for efficient processing of U122.
The putative SARS-CoV U122 signal sequence. Since the
deduced SARS-CoV U122 amino acid sequence contains a
putative signal peptide sequence of 15 residues (16), we spec-
ulated that the smaller15.0-kDa product was due to cleavage
of the signal peptide from the larger17.5-kDa protein. Signal
peptides play a major role in membrane integration and the
translocation of secretory and membrane proteins from the
ER (4). Many enveloped virus glycoproteins are synthesized as
inactive precursors, which are usually unable to mediate mem-
brane fusion and, hence, viral entry (28). Therefore, the endo-
proteolytic cleavage of viral envelope glycoproteins is crucial
for virus maturation, and the availability of cellular enzymes
capable of processing the inactive precursors can be major
determinants of viral tropism and pathogenicity (15, 28). To
determine whether the SARS-CoV signal peptide sequence is
active, we used PCR-directed mutagenesis to create two mu-
tations in U122, one in the cleavage site of the putative signal
peptide and the other to delete the N-terminal signal peptide
up to the cleavage site. Mutation of the residues spanning the
predicted cleavage site (residues SCELY at positions 14 to 18)
to leucines (U122-L) abolished the cleavage of U122 in Vero
E6-transfected cells (Fig. 3B, lane 1). The resultant17.5-kDa
product was similar in size to the untagged U122 immature
product. Also, transient expression of the deletion mutant
matU122 resulted in a product similar in size (15.0 kDa) to
the mature form of the U122 peptide (Fig. 3B, lane 2). Pulse-
chase analysis was done to determine the kinetics of wild-type
untagged U122 expression in mammalian cells. U122 was ex-
pressed and radiolabeled in Vero E6 cells, and the radiola-
beled U122 was immunoprecipitated. During the 2-h chase,
the level of immature U122 slowly decreased, while the detect-
able level of mature U122 remained fairly constant (Fig. 3C).
Expressed as a percentage of total U122 proteins, the imma-
ture form decreases, while the mature form increases through
the 2-h chase (Fig. 3D), indicating that the uncleaved form was
processed into the mature form. Both immature and mature
forms could be detected from the start of the pulse-chase (Fig.
3C, time zero), indicating that the immature protein was co-
translationally processed to form the smaller mature protein.
The total amount of labeled protein decreases, indicating that
U122 is degraded in the course of the experiment. Combining
these observations, we hypothesized that the constant level of
the mature form may be due to the replacement of degraded
mature protein by the conversion of immature protein to a
mature form. Most of the conversion of immature to mature
protein occurred cotranslationally (about 40%), and the re-
mainder of the cleavage was posttranslational (about 10%). At
the end of the 2-h pulse-chase, the processing was still not
complete and reached a plateau of about 50% by 90 min,
indicating that although posttranslational cleavage occurred, it
was fairly inefficient.
Mutation of the ER retrieval motif leads to rapid proteolytic
processing of U122. The short C-terminal tail of U122 contains
a typical ER retrieval motif, KRKTE. In mammals, plants, and
yeasts, this typical cytosolic C-terminal dilysine motif (KKXX
or KXKXX, where X is any amino acid) is crucial for ER
localization of type I membrane proteins (2, 11). If the C-
terminal X is considered the 1 position, the two lysine resi-
dues must be in the 3 and 4 or the 3 and 5 positions,
respectively. These two lysine residues cannot be replaced by
any other basic amino acid, and mutation of these residues
results in the abolishment of the ER localization of the re-
porter proteins of mammalian cells (11). Studies have shown
that the carboxyl-terminal sequence of Lys-X-Lys-X-X in inte-
gral ER membrane proteins functions either as a retrieval or
retention signal, with signals important for the transport of
these proteins back to the ER from the intermediate compart-
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FIG. 3. Processing of U122 expressed in Vero E6 cells. (A) Untagged U122 was translated in vitro and visualized by autoradiography. A single
band of 17.5 kDa was detected. (B) Untagged U122-L (lane 1), matU122 (lane 2), and U122 (lane 3) proteins were expressed in Vero E6 cells.
Total proteins were extracted by using RIPA buffer, and 20 g of total protein was used for SDS–15% PAGE. Western blots of these proteins were
probed with mouse anti-U122 antibodies. (C) Vero E6 cells were transfected with plasmid pXJU122 for pulse-chase analysis. At 6 h posttran-
fection, cells were starved for 30 min in cysteine- and methionine-deficient medium and subsequently labeled for 30 min with 35S-labeled amino
acids. Cells were either lysed directly (time zero) or chased for 30, 60, 90, or 120 min. Cell lysates were immunoprecipitated with mouse anti-U122
antibodies and separated on an SDS–15% PAGE gel, followed by autoradiography. (D) Quantification of the pulse-chase experiment. The amount
of immature (Œ) and mature (E) 35S-labeled U122 protein was determined with a densitometer and expressed as a percentage of the total labeled
protein at each time point (results are means 
 standard error of the means for two experiments). IP, immunoprecipitation; WB, Western blot;
m	U122, mouse anti-U122 antibody.
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ment (19). To determine whether this retrieval motif was func-
tional, the lysine residues at positions 118 and 120 were mu-
tated to glutamic acid by using PCR-directed mutagenesis
(U122KE). Transient expression of plasmid pXJU122KE
in Vero E6 cells was done to determine the effect of the
mutation on protein expression and localization. Total proteins
were harvested at 16 h posttransfection, subjected to Western
blotting, and probed with mouse anti-U122 (Fig. 4A). Two
bands (15.5 and 12.5 kDa) were detected in the cells ex-
pressing U122KE (Fig. 4A, lane 1), which were different in
size from those observed for U122. The processing of the
immature form appears to be very efficient, as the larger band
(17.5 kDa) is no longer visible. The two bands produced by the
mutant untagged protein differed in size from the smaller band
(15.0 kDa) of U122. The mutations from K to E may cause the
small change in mobility, or mutations in the recycling signal
may influence the processing of the U122 at the N terminus so
that the alternative cleavage sites are used. Pulse-chase anal-
ysis of U122KE was performed to verify the efficiency of this
processing. Following a 10-min pulse-labeling, the immature
17.5-kDa product was not detected at the start of the chase,
indicating that the immature product has been converted co-
translationally to two smaller products of 12.5 kDa (Fig. 4B).
Benghezal et al. (2) observed similar results with green fluo-
rescent protein-fusion proteins fused to mutated retrieval sig-
nals in plants. They suggested that the mutated retrieval signal
caused rapid protein exit from the ER to a distal compartment
where the processing activity is located. The larger band of the
doublet is eventually converted to the smaller 12.5-kDa
product after the 60-min chase, suggesting an additional pro-
teolytic cleavage site in the KE mutant (Fig. 4B).
SARS-CoV U122 is localized to the ER and ER-Golgi inter-
mediate compartment in transfected cells. The subcellular lo-
calization of U122 in Vero E6 cells was studied. At 16 h
posttransfection, cells were fixed with methanol and stained
with both mouse anti-U122 antibodies (Fig. 5, left frames) and
antibodies to either the ER marker GRP94 (Fig. 5, ii), the ER
intermediate compartment marker Sec31 (frame v) or the
Golgi marker GS28 (frames viii and xi). U122 was observed to
colocalize with GRP94 (Fig. 5, iii), indicating that U122 was
present in the ER compartment. In cells showing weaker U122
expression, U122- and Sec31-labeled punctate structures could
be detected. These probably corresponded to the ER-Golgi
intermediate compartment (Fig. 5, vi). U122 did not colocalize
with the cis-Golgi marker GS28 (Fig. 5, ix). This is likely due to
the rapid movement of U122 from the Golgi compartment
back to the ER, as seen in recycled proteins with retrieval
signals (6). On the other hand, mutant U122KE was pre-
dominantly localized to the Golgi (Fig. 5, xii). Following cleav-
age of the signal sequence, it is rapidly transported to the Golgi
but cannot be recycled back to the ER because of the mutated
retrieval sequence, resulting in a large fraction of U122KE
remaining in the Golgi apparatus. Collectively, immunofluo-
rescence results indicated that untagged U122 was cycled be-
tween the ER and Golgi compartments and that this process
was mediated by the retrieval motif at the C terminus.
Interestingly, convalescent-phase human sera could not de-
tect bacterially expressed U122-glutathione transferase fusion
protein by Western blot analysis (25). This suggests that U122
is either not a viral structural protein or that it is not exposed
or sufficiently immunogenic in vivo. Importantly though, U122
has been shown to interact specifically with another unique
group-specific SARS-CoV protein (ORF3a on sgRNA 3), des-
ignated U274 (Fig. 1). The latter has been shown to interact
with the SARS-CoV structural proteins E, S, and M (24). Also,
in this study U122 was shown to localize to the intermediate
compartment, where CoVs are known to assemble and bud
(12). Taken together, these results indicate that U122 might
have some yet undetermined role in virus replication, assem-
bly, or infection at least during in vivo infection. Further work
will be done to determine if U122 is a structural protein,
whether it plays a role in viral replication in vitro or in vivo, and
whether it is a novel SARS-CoV structural protein.
FIG. 4. The U122KE protein is rapidly processed in transfected
cells. (A) Untagged U122 and U122KE proteins were expressed in
transfected Vero E6 cells. At 16 h posttransfection total proteins were
extracted by using RIPA buffer and 20 g of protein separated on an
SDS–15% PAGE gel. Western blots of these proteins were probed
with mouse anti-U122 antibodies. (B) Vero E6 cells were transfected
with pXJU122KE for pulse-chase analysis. At 6 h posttranfection,
cells were starved for 30 min in cysteine- and methionine-deficient
medium and subsequently labeled for 10 min with 35S-labeled amino
acids. Cells were either lysed directly (time zero) or chased for 10, 20,
30, or 60 min. Cell lysates were immunoprecipitated with mouse anti-
U122 antibodies, followed by separation on an SDS–15% PAGE gel
and autoradiography. IP, immunoprecipitation; WB, Western blot;
m	U122, mouse anti-U122 antibody.
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FIG. 5. Intracellular localization of expressed U122 and retrieval signal mutant. Vero E6 cells were transfected with plasmid pXJU122 or
pXJU122KE. At 16 h posttransfection, cells were fixed with methanol and labeled with mouse anti-U122 antibody (left panels) and either
antibodies to the ER marker GRP94 (rat anti-GRP94), the intermediate compartment marker Sec31 (rabbit anti-Sec31), or Golgi marker GS28
(rabbit anti-GS28) (middle panels). When anti-U122 was used with anti-GS28 or anti-Sec31, FITC-conjugated goat anti-mouse and Rh-conjugated
anti-rabbit antibodies (Santa Cruz Biochemicals) were used as secondary antibodies. For double labeling with anti-U122 and anti-GRP94,
FITC-conjugated anti-rat and Rh-conjugated anti-mouse (Santa Cruz Biochemicals) antibodies were used as secondary antibodies. Merged images
showed colocalization of U122 and KE proteins with the marker proteins (right panels).
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